Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 103 clinical trials
A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies

CA-4948 either as monotherapy (Part A1) or in combination with ibrutinib for nonHodgkin' s Lymphoma (NHL), macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) and chronic lymphocytic leukemia (CLL

  • 17 views
  • 12 May, 2021
  • 11 locations
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

The purpose of this study is to determine the most appropriate dose for the combination of ibrutinib and pembrolizumab and to see if the combination is active for the disease. The study will

lymphoma
leukemia
tyrosine
mantle cell lymphoma
hematologic malignancy
  • 88 views
  • 15 Mar, 2021
  • 1 location
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvica). At this stage of this trial, the study is investigating whether

  • 27 views
  • 24 Jan, 2022
  • 7 locations
Ibrutinib Rituximab Etoposide Prednisone Vincristine Sulfate Cyclophosphamide and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride

  • 130 views
  • 23 Sep, 2021
  • 18 locations
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

during treatment with ibrutinib or acalabrutinib.

17p deletion
ibrutinib
chronic lymphocytic leukemia
TP53
measurable disease
  • 4 views
  • 04 Aug, 2021
  • 7 locations
Dasatinib In Waldenstr m Macroglobulinemia

This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenstrm Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK

neutrophil count
bone marrow procedure
lymphadenopathy
platelet count
potassium
  • 2 views
  • 24 Nov, 2021
Personalized Multi-peptide Vaccination in CLL Patients

ibrutinib-based regimes.

corticosteroids
night sweats
lymphadenopathy
anemia
flow cytometry
  • 0 views
  • 18 Sep, 2021
  • 1 location
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

are currently on treatment with ibrutinib, alacabrutinib or venetoclax.

residual tumor
lymphoid leukemia
acalabrutinib
monoclonal protein
ibrutinib
  • 1 views
  • 21 Jan, 2022
  • 2 locations
A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

This is a open-labelmulticenter, randomised, three-arm, phase II efficacy and safety study of ibrutinib in combination with MRE(methotrexate,rituximab,etoposide)-chemotherapy versus lenalidomide

  • 0 views
  • 23 Jul, 2021
  • 1 location
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

The primary objective of the study is to establish a pharmacologically active dose of mavorixafor in combination with ibrutinib based on pooled safety, clinical response, pharmacokinetic (PK

neutrophil count
direct bilirubin
bone marrow procedure
igm level
ibrutinib
  • 12 views
  • 22 Aug, 2021
  • 4 locations